Printer Friendly

THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT

 THERAGENICS RECORDS RECORD FOURTH QUARTER AND YEAR END RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 227 PERCENT
 ATLANTA, Feb. 3 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, today announced that, for the fourth quarter ended Dec. 31, 1991, the company recorded a net profit of $259,484, or $.03 per share, compared to a net loss of $174,350, or $(.02) per share, for the same period last year.
 Theragenics' revenue for the fourth quarter of fiscal 1991 was $874,150, a 227 percent improvement on the $267,230 in revenue recorded for the fourth quarter of 1990.
 For the year ended Dec. 31, 1991, Theragenics recorded a net profit of $725,579, or $.07 per share, compared to a net loss of $597,308, or $(.06) per share, for 1990.
 The company's revenue for fiscal 1991 was $2,769,413, a 141 percent improvement over the $1,148,833 in revenue recorded for 1990.
 President and CEO John V. Herndon said, "We are extremely satisfied that we were able to significantly outperform our aggressive sales goal of growing our 1991 revenues 100 percent. We are also proud that our 1991 fourth quarter profit was almost as great as our sales for the fourth quarter of 1990."
 Theragenics has demonstrated a strong sales trend over the past three years, with revenues of $533,622 in 1989, $1,148,833 in 1990 and $2,769,413 in 1991. Herndon said he expected this trend to continue, projecting 1992 sales of $6 million. "Although there are no guarantees in the fast changing medical world," he said, "we have nevertheless demonstrated an ability to consistently meet or exceed our objectives. Our sales growth in 1991 and our expectations for 1992 indicate exciting possibilities for 1993 and beyond as well."
 Theragenics manufactures and markets TheraSeed, a nonsurgical, outpatient treatment which uses implanted Palladium 103 seeds to eradicate prostate cancer. The product is now used at more than 90 clinics and hospitals nationwide.
 THERAGENICS CORP.
 Consolidated Statement of Operations
 (Unaudited)
 Periods ended Three Months Year
 Dec. 31 1991 1990 1991 1990
 Revenues $874,150 $267,230 $2,769,413 $1,148,833
 Net profit (loss) 259,484 (174,350) 725,579 (597,308)
 Earnings (loss)
 per share $.03 ($.02) $.07 ($.06)
 Fully diluted .02 (.02) .06 (.05)
 -0- 2/3/92
 /CONTACT: Bruce Smith, CFO of Theragenics, 404-381-8338; or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX) CO: Theragenics Corp. ST: Georgia IN: MTC SU: ERN


GK-TH -- NY016 -- 6029 02/03/92 09:28 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 3, 1992
Words:426
Previous Article:DON GANGEMI OF WANG APPOINTED TO COMPUTER SECURITY ADVISORY BOARD
Next Article:STATE OF THE ART INC. ANNOUNCES NATIONAL CONSULTING AGREEMENT WITH PROMINENT REGIONAL ACCOUNTING FIRM MOSS ADAMS
Topics:


Related Articles
THERAGENICS RECORDS THIRD CONSECUTIVE PROFITABLE QUARTER; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS REVENUE 120 PERCENT
BELLINGHAM INDUSTRIES ACQUIRES 24.1 PERCENT OF THERAGENICS
THERAGENICS NAMES CHRISTINE JACOBS PRESIDENT AND C.O.O.
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ACHIEVES RECORD SECOND QUARTER RESULTS; SUCCESS OF CANCER THERAPY PRODUCT BOOSTS QUARTERLY REVENUE 121 PERCENT
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT
THERAGENICS ANNOUNCES 1993 RESULTS
Medtronic Quarterly Earnings Per Share Rise 30 Percent On 25 Percent Growth In Revenues; Annual Revenues Top a Record $5 Billion.
ABAXIS Reports Record Financial Results for the Fourth Quarter and Fiscal Year 2004;.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters